William Audeh, MD, MS, Chief Medical Officer at Agendia, is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

Dr. Gilmore is a board-certified anatomic pathologist specializing in breast pathology at University Hospitals Cleveland Medical Center and Associate Professor of Pathology at Case Western Reserve University in Cleveland, Ohio. Dr. Gilmore has published widely on the pathogenesis of breast tumors and the identification of their diagnostic, predictive and prognostic markers. As the Division Chief of Anatomic Pathology, she made innovative changes to the practice of the discipline with emphasis on subspecialization, multidisciplinary care, molecular diagnostics and digital pathology. She is the College of American Pathologists representative to the National Accreditation Program for Breast Centers where she is Vice Chair of the Standards and Accreditation Committee.

William Audeh, MD, MS, Chief Medical Officer at Agendia, is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

Dr. Gilmore is a board-certified anatomic pathologist specializing in breast pathology at University Hospitals Cleveland Medical Center and Associate Professor of Pathology at Case Western Reserve University in Cleveland, Ohio. Dr. Gilmore has published widely on the pathogenesis of breast tumors and the identification of their diagnostic, predictive and prognostic markers. As the Division Chief of Anatomic Pathology, she made innovative changes to the practice of the discipline with emphasis on subspecialization, multidisciplinary care, molecular diagnostics and digital pathology. She is the College of American Pathologists representative to the National Accreditation Program for Breast Centers where she is Vice Chair of the Standards and Accreditation Committee.

William Audeh, MD, MS, Chief Medical Officer at Agendia, is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

David Hicks, MD, Professor and Director of IHC-ISH Laboratory and Breast Subspecialty Service at URMC. His innovative approaches to improving efficiency and quality in surgical pathology have been highlighted in publications and invited lectures sponsored by national pathology organizations. He has implemented a subspecialty-based surgical pathology system, combining disease-specific diagnostic and prognostic expertise with translational research based on organ systems and disease categories. As a member of the Ad Hoc Committee on Immunohistochemistry Standardization, and co-author of their consensus recommendations.